期刊
BIOMEDICINE & PHARMACOTHERAPY
卷 71, 期 -, 页码 135-138出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2015.02.031
关键词
Cancer stem cells; CD26; CSC marker; Indifferentiation marker; Therapeutic target
资金
- CNPq-Brazil
- CAPES-Brazil
- FAPERGS (Fundacao de Amparo a Pesquisa do Rio Grande do Sul) [PPSUS 1154-2551/13-1]
- CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) [Universal 312174/2013-6]
Cancer stem cells (CSCs) comprise a tumor subpopulation responsible for tumor maintenance, resistance to chemotherapy, recurrence and metastasis. The identification of this cell group is very important, but there is still no consensus on its characterization. Several CSC markers have been described, like CD133, CD24, CD44 and ALDH1, but more research to identify new markers to facilitate the identification of CSC in a heterogeneous tumoral mass is required. Thus, this article describes the CD26 expression as a CSC marker and the role that it plays in different types of cancer. CD26 expression correlates with some characteristics of CSCs, like the formation of spheres in vitro, formation of new tumors, and resistance to chemotherapy. CD26 is therefore suggested as an auxiliary marker for CSC in different types of cancer, and as a potential therapeutic target. (C) 2015 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据